INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|---|
Oct. 12, 2018 |
Jul. 28, 2016 |
Jan. 26, 2016 |
Sep. 30, 2018 |
Sep. 30, 2017 |
Sep. 30, 2018 |
Sep. 30, 2017 |
Dec. 31, 2017 |
|
| Intellectual property fees | $ 55,648 | |||||||
| Description for right to purchase perpetual rights | <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">North America with the option for Central and South America for Naltrexone Implants formulas created by the Seller for 24 months upon receipt of the intellectual property for a fee of $55,648. The Company, within the first 12 months has the right to purchase perpetual rights for above territories for a one-time fee, financed over 5 years. The rights are amortized over the 24 month contract life.</font></p> | |||||||
| Amortization expenses | $ 0 | $ 7,013 | $ 1,963 | $ 20,810 | ||||
| Therakine, Ltd. [Member] | ||||||||
| License cost | $ 2,750,000 | |||||||
| Aggregate purchase price | $ 250,000 | $ 250,000 | $ 250,000 | |||||
| Escrow deposit | $ 75,000 | |||||||
| Therakine, Ltd. [Member] | Minimum [Member] | ||||||||
| Milestone payments and royalties | 5.00% | |||||||
| Therakine, Ltd. [Member] | Maximum [Member] | ||||||||
| Milestone payments and royalties | 12.00% | |||||||
| Subsequent Event [Member] | Therakine Biodelivery GmbH [Member] | ||||||||
| Patent acquired | $ 15,200 | |||||||
| Development, Commerialization and License agreement, description | <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Patent families consisting of approximately 11 patents pending and 1 issued patent.</font></p> | |||||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of tax incurred and cost of license directly related to good produced or service rendered. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|